Welcome to our dedicated page for Pulmonx SEC filings (Ticker: LUNG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pulmonx Corporation (Nasdaq: LUNG) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, periodic reports, and exhibits filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into Pulmonx’s financial condition, executive transitions, compensation arrangements, and key business developments related to its minimally invasive treatments for COPD and severe emphysema.
Pulmonx uses Form 8-K to report material events such as quarterly financial results and management changes. For example, a July 2025 Form 8-K furnished a press release titled “Pulmonx Reports Second Quarter 2025 Financial Results,” while an October 2025 Form 8-K described the resignation of the then-President and Chief Executive Officer, the appointment of Glen French as President and Chief Executive Officer, and the appointment of Derrick Sung as Chief Operating Officer and Chief Financial Officer. That filing also outlined separation agreements, consulting arrangements, and equity grants for departing and incoming executives.
Through its SEC filings, Pulmonx also discloses equity compensation structures, including restricted stock units (RSUs) and performance stock units (PSUs) granted under its equity incentive plans and inducement plans. The terms of these awards, such as time-based vesting schedules and stock price performance conditions, are described in detail in the exhibits to the filings.
On Stock Titan, Pulmonx filings are updated in step with the SEC’s EDGAR system, and AI-powered summaries help explain the key points of lengthy documents. Investors can quickly identify information on quarterly and annual results, executive employment terms, severance and change in control plans, and other governance matters without reading every page of each filing. The filings page also helps users locate references to non-GAAP metrics like Adjusted EBITDA and constant currency revenue, which Pulmonx discusses in its earnings-related disclosures.
Pulmonx Corporation entered into a new senior secured term loan facility of up to
The loan matures on
In connection with the financing, Pulmonx issued Perceptive a warrant to purchase 1,000,000 common shares at an exercise price of
Pulmonx Corp’s Chief Science & Technology Officer, Radhakrishnan Srikanth, reported routine equity-related transactions in company common stock. On March 2, 2026, he sold a total of 10,483 shares at
On the same date, he received a grant of 175,000 RSUs, payable solely in Pulmonx common stock, which will vest in equal quarterly installments over a four-year period starting on
Pulmonx Corp President and CEO Glendon E. French III reported open-market sales of 67,813 shares of common stock. The sales occurred on
Pulmonx Corp reported insider transactions by its Chief Commercial Officer, Geoffrey Beran. On March 2, 2026, he sold a total of 7,732 shares of common stock at $1.43 per share in open-market sales to cover tax withholding obligations tied to vesting restricted stock units granted in 2022, 2023, 2024, and 2025.
On the same date, he received a grant of 100,000 restricted stock units, payable solely in Pulmonx common stock, which vest in equal quarterly installments over four years from March 2, 2026. Following these transactions, his direct holdings increased to 465,734 shares of common stock.
Pulmonx Corp’s general counsel, David Aaron Lehman, reported multiple insider transactions in Pulmonx common stock. On March 2, 2026, he sold a total of 12,237 shares in open‑market transactions at $1.43 per share. Footnotes state these sales were made to cover tax withholding obligations tied to the vesting of restricted stock units (RSUs) granted between March 1, 2022 and March 3, 2025, indicating they were not discretionary portfolio sales. On the same date, he received a grant of 150,000 RSUs payable solely in common stock, vesting in equal quarterly installments over four years from March 2, 2026. Following these transactions, his directly held Pulmonx shares increased to 390,755.
Pulmonx Corporation reported mixed fourth quarter and full-year 2025 results while issuing cautious 2026 guidance. Full-year 2025 revenue reached $90.5 million, up 8% from 2024, driven by 23% international growth, while U.S. revenue grew 1%. Fourth quarter revenue was $22.6 million, down 5% year over year, as U.S. sales declined 11% but international revenue rose 8%.
Profitability metrics improved modestly. Full-year gross profit was $67.1 million with a 74% gross margin, and fourth quarter gross margin increased to 78%. The company narrowed its net loss to $54.0 million for 2025, or $1.33 per share, from a $56.4 million loss in 2024, and reduced its adjusted EBITDA loss to $30.6 million.
Pulmonx ended 2025 with $69.8 million in cash, cash equivalents, and marketable securities, down about $32 million over the year. It refinanced its debt with a new 5-year interest-only credit facility providing up to $60 million and extending maturity to 2031, and executed a cost restructuring to lower operating expenses. For 2026, the company guides revenue to $90–$92 million, gross margin around 75%, operating expenses of $113–$115 million (including about $21 million of stock-based compensation), and expects cash and investments to decline by roughly $23 million, assuming no further credit facility drawdowns.
A shareholder of NASDAQ-listed LUNG, identified as Steven Williamson, has filed a Rule 144 notice to sell 48,892 shares of common stock through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of 95,339.40 for these shares, with 41,247,034 shares outstanding for the issuer. The planned sale is to be executed on or about 01/22/2026 on the NASDAQ exchange.
The notice also reports that during the past three months, the same seller disposed of additional common shares, including 15,892 shares on 01/15/2026 for gross proceeds of 31,038.67 and 31,082 shares on 01/14/2026 for gross proceeds of 62,073.62. The securities to be sold in this notice were acquired as restricted stock directly from the issuer in several transactions during 2025.
Steven Williamson has filed a notice of proposed sale under Rule 144 to sell 15,892 shares of common stock of LUNG through Morgan Stanley Smith Barney LLC at an aggregate market value of $31,038.67, with the shares listed on NASDAQ. The filing notes that 41,247,034 shares of this class were outstanding, providing context for the planned sale size.
The shares to be sold come from restricted stock acquired from the issuer on March 3, 2025 (11,796 shares) and June 1, 2025 (4,096 shares), both marked as not involving special payment arrangements. Over the prior three months, Williamson sold 31,082 common shares for gross proceeds of $62,073.62. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about LUNG’s current or prospective operations.
A shareholder of LUNG has filed a notice of proposed sale under Rule 144 to sell 31,082 common shares through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of 62,073.62 for these shares, with an approximate sale date of January 14, 2026 on NASDAQ. The notice also shows that 41,247,034 common shares are outstanding and that the shares to be sold were acquired via restricted stock, open market purchases, and an employee stock purchase plan.
Pulmonx Corp reported new equity awards to its Chief Operating Officer and Chief Financial Officer on December 1, 2025. The executive received 1,200,000 Restricted Stock Units that are payable in common stock. According to the terms, 25% of these units vest one year after the grant date, with the remaining balance vesting in equal quarterly installments over the following three years.
The executive also received 400,000 Performance Stock Units, each tied to one share of common stock. These units vest only if two conditions are met: the company’s stock reaches a specified price per share and time-based milestones are satisfied, with 33% vesting one year after the grant date and the rest in eight equal quarterly installments through December 1, 2028. Both awards are shown at a price of $0, reflecting that they are equity incentives rather than open-market purchases.